Epidemiology & Incidence

Clinical Pearl: Cisplatin is the #1 cause of chemotherapy-induced acute kidney injury, accounting for ~20–30% AKI incidence at standard doses (70–100 mg/m²) and up to 70–80% with cumulative high-dose exposure (>500 mg/m²).

• Cumulative dose-dependent: Risk escalates significantly above 300 mg/m² lifetime
• Acute AKI typically reversible (Cr rise within days 3–7, recovery over 2–4 weeks)
• Chronic kidney disease: 10–30% of cisplatin-treated patients develop lasting eGFR decline (stage 3–4 CKD)
• Hypomagnesemia: 40–100% depending on dose and follow-up duration

Mechanism of Proximal Tubule Injury [1,2,3]

Key Point: Cisplatin nephrotoxicity is fundamentally a proximal tubule disease, not glomerular.

Clinical Presentation of Cisplatin AKI

Complicating Renal Lesions

Epidemiology & Renal Tolerability

• Incidence of AKI: <5% (vs. 20–30% for cisplatin)
• Incidence of hypomagnesemia: <10%
• Reason: Carboplatin is less nephrotoxic due to different chemical structure and reduced proximal tubule uptake

Calvert Formula & Dose Adjustment in CKD

Key Point: Carboplatin dosing is AUC-based (area under curve), NOT flat mg/m². This is critical for dose adjustment in renal impairment.

Calvert Formula:

Dose (mg) = AUC × (GFR + 25)
GFR = (140 - age) × weight(kg) / (72 × Cr[mg/dL])
      × 0.85 if female

Clinical Pearl: - Standard AUC = 6.0 mg·min/mL (or target specified by protocol) - In CKD (eGFR 30–60): Calculate actual GFR; usually minor dose reduction - In CKD (eGFR <30): Significant dose reduction; often discontinue if eGFR <20 (hematologic toxicity becomes dose-limiting) - Renal function should be re-assessed before each cycle

Renal Side Effects

• Thrombocytopenia: Dose-limiting (NOT nephrotoxicity)
• Minimal direct renal toxicity: No hypomagnesemia, rare AKI
• Electrolyte abnormalities: Uncommon
• Acceptable in moderate CKD: But watch for accumulation if creatinine clearance <50

Renal Safety Profile

• Nephrotoxicity: Extremely rare (<1% incidence of AKI)
• Hypomagnesemia: Uncommon
• Main dose-limiting toxicity: Acute neurotoxicity (reversible) and cumulative peripheral neuropathy (CIPN)

Occasional Renal Presentations

Aggressive Hydration: The Gold Standard

Board Point: Pre- and post-treatment hydration is the single most effective preventive measure for cisplatin nephrotoxicity.

Clinical Pearl: Hydration is the reason carboplatin is “safer” — dose reduction already accounts for renal impairment. Cisplatin in CKD requires aggressive hydration to mitigate risk.

Mannitol or Forced Diuresis (Controversial)

Old dogma: Mannitol + furosemide (“forced diuresis”) offered additional protection.

Current evidence: - No clear superiority over hydration alone [3] - Diuretics may impair Mg reabsorption → worsens hypomagnesemia - Can worsen electrolyte wasting (Na, K, Mg) - Recommendation: Reserve for volume overload only; not routine

Amifostine: Selective Protector

Mechanism: Free radical scavenger; protects normal tissue while preserving tumor Pt uptake.

Evidence: - Reduces AKI incidence by ~30–40% in cisplatin-treated patients [published trials] - Reduces hypomagnesemia by ~20–30% - Cost: ~$500–$1000 per dose - Side effects: Hypotension (transient), nausea, allergy reactions

Current use: Reserved for salvage cisplatin in patients with baseline CKD or prior high cumulative dose. Not routine.

Magnesium Supplementation (CRITICAL PREVENTION)

Key Point: Prophylactic Mg replacement before/during cisplatin can reduce hypomagnesemia incidence and improve patient tolerability.

Recent evidence (2025): Magnesium may limit platinum accumulation in tubular cells by modulating OCT2 and other renal transporters, providing mechanistic rationale for prevention [recent review].

Baseline & Pre-Treatment Assessment

• Serum Cr, eGFR: Establish baseline; reassess within 72 hours post-treatment
• Urine electrolytes & output: Baseline for comparison
• Magnesium, potassium, phosphate, calcium: Comprehensive metabolic panel
• Audiometry: Cisplatin causes hearing loss (high-frequency); baseline audiology recommended for high-dose regimens
• 24-hour urine protein: Baseline; repeat monthly if proteinuria develops

Monitoring Schedule During & After Treatment

Red Flags Requiring Intervention

• Cr rise >30% from baseline → discuss with oncology; consider dose reduction, hold cycle
• Serum Mg <1.5 mg/dL → IV repletion; assess for symptomatic hypomagnesemia
• Urine output <500 mL/day despite hydration → assess volume status; possible AKI
• Proteinuria >2 g/day → evaluate with UA/urine electrophoresis; rule out concomitant glomerular disease

Decision Tree: When to Switch or Adjust

eGFR Assessment:
├─ eGFR ≥45: Cisplatin standard dose feasible
│  └─ Require aggressive hydration + baseline Mg repletion
├─ eGFR 30–44: Reduced cisplatin dose (50–75%) OR switch to carboplatin
│  └─ Discuss with oncology; carboplatin preferred if chemotherapy non-curative
├─ eGFR <30: Carboplatin preferred
│  └─ Cisplatin generally contraindicated (cumulative toxicity risk)
└─ On dialysis: Use carboplatin (easier dosing, less ototoxicity)
   └─ Coordinate with dialysis schedule; consider HD timing relative to chemo

Practical Dosing Adjustments

Board Point: eGFR <30 + cisplatin = high-risk combination; cisplatin-induced AKI can precipitate need for dialysis in this population.

Persistent eGFR Decline Post-Therapy

Key Statistic: 10–30% of cisplatin-treated patients have lasting ≥10 mL/min decline in GFR compared to baseline, persisting years to decades post-therapy.

• Mean decline: 10–15 mL/min/1.73m² (when cumulative dose >300 mg/m²)
• Risk factors for chronic sequelae:
  • Cumulative dose >400 mg/m²
  • Baseline CKD or risk factors (hypertension, diabetes)
  • Older age at treatment
  • Concomitant nephrotoxic agents (amphotericin B, NSAIDs)

Proteinuria in Survivors

• Incidence: 15–25% have persistent low-grade proteinuria (<1 g/day)
• Mechanism: Tubular dysfunction (Fanconi syndrome component)
• Significance: Not nephrotic; usually benign; correlates with degree of proximal tubule injury
• Management: Monitor annually; RAAS inhibition if HTN

Ototoxicity & Renal Outcomes (Shared Mechanism)

Clinical Pearl: Cisplatin-induced hearing loss and nephrotoxicity share similar mechanisms (oxidative stress, mitochondrial dysfunction). Patients with severe ototoxicity often have worse renal outcomes.

Long-Term Follow-Up Recommendations

• Annual Cr/eGFR: For life (or until stable ×3 years)
• Baseline CKD risk stratification: HTN control, diabetes management
• Avoid nephrotoxic agents: NSAIDs, ACE-I/ARB if eGFR <30 (unless specific indication)
• Audiology follow-up: If significant hearing loss, may indicate need for closer renal monitoring

Algorithm 1: Pre-Chemotherapy Renal Assessment

Patient with planned platinum chemotherapy
    ↓
Measure Cr, calculate eGFR (KDIGO 2021 formula)
    ↓
eGFR ≥45? → Yes → Cisplatin feasible → Plan aggressive hydration + Mg repletion
             No ↓
Discuss with oncology: curative vs. palliative intent?
    ├─ Curative → Switch to carboplatin OR reduce cisplatin + enhanced hydration
    └─ Palliative → Consider non-platinum agents; carboplatin if Pt essential
    ↓
Assess volume status, CHF, cirrhosis
    ├─ Yes → Careful fluid management; consider amifostine
    └─ No → Standard hydration protocol
    ↓
Check baseline Mg, K, PO4; start Mg repletion if low-normal
    ↓
Plan post-treatment monitoring (see table above)

Algorithm 2: Management of Platinum-Induced AKI

Post-platinum AKI (Cr rise ≥30% from baseline within 3–7 days)
    ↓
Assess volume status & urine output
    ├─ Hypovolemic → Fluid resuscitation; target UOP 100–200 mL/hr
    ├─ Euvolemic → Maintenance hydration
    └─ Hypervolemic → Diuretics; hold further hydration; assess for CHF/cirrhosis
    ↓
Check metabolic panel urgently: K↑?, Mg↓?, PO4↑?
    ├─ Hyperkalemia → Treat per AKI protocol (insulin, bicarb, kayexalate)
    ├─ Hypomagnesemia → IV Mg 10–20 mEq q8h; recheck q4h if severe
    └─ Hyperphosphatemia → Assess for TLS; phosphate binders if needed
    ↓
Determine Cr trajectory
    ├─ Improving (Cr declining) → Continue hydration; step down as Cr stabilizes
    ├─ Stable → Maintenance hydration; monitor closely
    └─ Worsening (Cr still rising) → ↓ UOP after day 5? Consider dialysis consult
    ↓
Assess need for continued chemotherapy
    ├─ Reversible AKI + curative regimen → Resume next cycle (eGFR permitting)
    └─ Severe/persistent AKI → Switch to carboplatin or non-Pt agents
    ↓
Long-term: Plan electrolyte repletion regimen; monthly Cr checks ×3 months

CTCAE v5.0 Grading for Renal Dysfunction

Threshold for Holding Cisplatin Doses

• Absolute: eGFR <20 (carboplatin preferred)
• Relative: eGFR 20–30 + AKI in prior cycle
• Physician discretion: eGFR 30–45 + cumulative dose >300 mg/m² (may switch to carboplatin or reduce intensity)